GBAF Logo
Global Banking & Finance Awards® 2026 Nominations open, free to enter Nominate now →
S

SciClone Pharmaceuticals (Holdings) 6600.HK · HKD

Health Care · HKEX · 🇭🇰 Hong Kong

Compare

50.30

+2.28%

Close of 9 Nov 2026, in HKD

Search any instrument

Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.

About SciClone Pharmaceuticals (Holdings)

Its shares trade on HKEX under the ticker 6600.HK. It has been listed since 3 March 2021. In the fiscal year to 31 December 2023, it reported revenue of CN¥3.16bn and net income of CN¥1.12bn. At that date it held total assets of CN¥4.00bn and shareholders' equity of CN¥3.27bn.

SciClone Pharmaceuticals (Holdings) Ltd. is an investment holding company which manufactures and markets immune and oncology pharmaceutical products. The company is headquartered in Shanghai, Shanghai. The company went IPO on 2021-03-03. The firm primarily engages in the sales of its proprietary product, Zadaxin, its in-licensed products and promotion products on behalf of its business partners in China.

Figures and description from our data supplier, not checked against the company's own report.

Company facts

Sector
Health Care
Industry
Pharmaceuticals
Listed since
3 Mar 2021
Employees
1,000

Leadership

Pay as last reported

  • Mr. Zhenfu LiNon-Executive Chairman of the Board
  • Mr. Hong ZhaoPresident, Chief Executive Officer, Executive Director, since 2013CN¥25.8m
  • Ms. Rongrong PanChief Financial Officer, Vice President, Executive Director, Joint Company Secretary, since 2020
  • Mr. Yansong ChangVice President, Vice President and General Manager of Oncology Business Unit
  • Dr. Xiaoning GuoChief Medical Officer, Vice President, Head of Research and Development Department
  • Mr. Min JiaVice President and Head of Immunization Business Department
  • Mr. Chihwen ShaoVice President
  • Mr. Lianzong WuVice President
  • Mr. Mingxiang WuVice President
  • Ms. Sin Man ChanJoint Company Secretary
  • Ms. Yi-Hsien LinNon-Executive Director
  • Dr. Daniel VasellaNon-Executive DirectorCN¥569,000

Environmental, social and governance

Scores out of 100, from our data supplier

ESG
Overall
0
Environment
0
Social
0
Governance
0

SWOT analysis

AI-generated by our data supplier. Not written or checked by our editors.

AI-generated

Strengths

  • Zadaxin is a key proprietary product driving sales in China's oncology market.
  • SciClone employs 1,000 full-time employees supporting its pharmaceutical operations.
  • The company's focus on immune and oncology products aligns with growing healthcare demands.

Weaknesses

  • The company's reliance on Zadaxin for sales may limit product diversification.
  • Limited international presence beyond China's pharmaceutical market.
  • Dependence on in-licensed products for revenue generation.

Opportunities

  • Expanding Zadaxin sales into new oncology segments within China.
  • Growing demand for immune and oncology treatments in China's healthcare sector.
  • Potential partnerships for in-licensed products in the Chinese market.

Threats

  • Competition from other pharmaceutical companies in China's oncology market.
  • Regulatory changes affecting pharmaceutical sales in China.
  • Economic downturns impacting healthcare spending in China.

Sources and methodology

Data on this tab
Our data supplier
Chart on the Overview
TradingView

Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.